S&P 500   5,051.38 (-0.21%)
DOW   37,798.77 (+0.17%)
QQQ   432.03 (+0.23%)
AAPL   169.80 (-1.67%)
MSFT   415.82 (+0.53%)
META   501.22 (+0.20%)
GOOGL   154.69 (-0.11%)
AMZN   183.82 (+0.11%)
TSLA   157.28 (-2.60%)
NVDA   876.78 (+1.95%)
AMD   163.97 (+2.28%)
NIO   3.82 (-1.80%)
BABA   69.69 (-1.32%)
T   16.09 (-0.92%)
F   12.17 (-0.49%)
MU   121.86 (+0.40%)
GE   156.78 (+2.00%)
CGC   6.71 (-3.87%)
DIS   114.06 (+0.98%)
AMC   2.77 (+12.15%)
PFE   25.75 (-0.62%)
PYPL   63.71 (+0.31%)
XOM   118.81 (-0.73%)
S&P 500   5,051.38 (-0.21%)
DOW   37,798.77 (+0.17%)
QQQ   432.03 (+0.23%)
AAPL   169.80 (-1.67%)
MSFT   415.82 (+0.53%)
META   501.22 (+0.20%)
GOOGL   154.69 (-0.11%)
AMZN   183.82 (+0.11%)
TSLA   157.28 (-2.60%)
NVDA   876.78 (+1.95%)
AMD   163.97 (+2.28%)
NIO   3.82 (-1.80%)
BABA   69.69 (-1.32%)
T   16.09 (-0.92%)
F   12.17 (-0.49%)
MU   121.86 (+0.40%)
GE   156.78 (+2.00%)
CGC   6.71 (-3.87%)
DIS   114.06 (+0.98%)
AMC   2.77 (+12.15%)
PFE   25.75 (-0.62%)
PYPL   63.71 (+0.31%)
XOM   118.81 (-0.73%)
S&P 500   5,051.38 (-0.21%)
DOW   37,798.77 (+0.17%)
QQQ   432.03 (+0.23%)
AAPL   169.80 (-1.67%)
MSFT   415.82 (+0.53%)
META   501.22 (+0.20%)
GOOGL   154.69 (-0.11%)
AMZN   183.82 (+0.11%)
TSLA   157.28 (-2.60%)
NVDA   876.78 (+1.95%)
AMD   163.97 (+2.28%)
NIO   3.82 (-1.80%)
BABA   69.69 (-1.32%)
T   16.09 (-0.92%)
F   12.17 (-0.49%)
MU   121.86 (+0.40%)
GE   156.78 (+2.00%)
CGC   6.71 (-3.87%)
DIS   114.06 (+0.98%)
AMC   2.77 (+12.15%)
PFE   25.75 (-0.62%)
PYPL   63.71 (+0.31%)
XOM   118.81 (-0.73%)
S&P 500   5,051.38 (-0.21%)
DOW   37,798.77 (+0.17%)
QQQ   432.03 (+0.23%)
AAPL   169.80 (-1.67%)
MSFT   415.82 (+0.53%)
META   501.22 (+0.20%)
GOOGL   154.69 (-0.11%)
AMZN   183.82 (+0.11%)
TSLA   157.28 (-2.60%)
NVDA   876.78 (+1.95%)
AMD   163.97 (+2.28%)
NIO   3.82 (-1.80%)
BABA   69.69 (-1.32%)
T   16.09 (-0.92%)
F   12.17 (-0.49%)
MU   121.86 (+0.40%)
GE   156.78 (+2.00%)
CGC   6.71 (-3.87%)
DIS   114.06 (+0.98%)
AMC   2.77 (+12.15%)
PFE   25.75 (-0.62%)
PYPL   63.71 (+0.31%)
XOM   118.81 (-0.73%)
OTCMKTS:ENZN

Enzon Pharmaceuticals (ENZN) Stock Price, News & Analysis

$0.07
-0.02 (-21.10%)
(As of 04/15/2024 ET)
Today's Range
$0.06
$0.09
50-Day Range
$0.06
$0.10
52-Week Range
$0.06
$0.23
Volume
55,500 shs
Average Volume
14,496 shs
Market Capitalization
N/A
P/E Ratio
7.49
Dividend Yield
N/A
Price Target
N/A
ENZN stock logo

About Enzon Pharmaceuticals Stock (OTCMKTS:ENZN)

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.

ENZN Stock Price History

ENZN Stock News Headlines

Enzon Pharmaceuticals Inc ENZN
OKYO Pharma Limited (OK10.F)
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Enzon Stock Hits New 52-Week Low (ENZN)
Ibnsina Pharma Co (ISPH)
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Enzon Pharmaceuticals, Inc. (ENZN)
See More Headlines
Receive ENZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/20/2024
Today
4/16/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
OTCMKTS:ENZN
Previous Symbol
NASDAQ:ENZN
CUSIP
29390410
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$1.37 million
Pretax Margin
3,573.08%

Debt

Sales & Book Value

Annual Sales
$30,000.00

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.33
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

ENZN Stock Analysis - Frequently Asked Questions

How have ENZN shares performed in 2024?

Enzon Pharmaceuticals' stock was trading at $0.0936 at the beginning of the year. Since then, ENZN shares have decreased by 20.1% and is now trading at $0.0748.
View the best growth stocks for 2024 here
.

Are investors shorting Enzon Pharmaceuticals?

Enzon Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 3,800 shares, an increase of 137.5% from the March 15th total of 1,600 shares. Based on an average trading volume of 50,100 shares, the days-to-cover ratio is currently 0.1 days.
View Enzon Pharmaceuticals' Short Interest
.

How were Enzon Pharmaceuticals' earnings last quarter?

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) announced its quarterly earnings results on Wednesday, March, 20th. The biotechnology company reported $0.01 EPS for the quarter.

What other stocks do shareholders of Enzon Pharmaceuticals own?
How do I buy shares of Enzon Pharmaceuticals?

Shares of ENZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ENZN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners